CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
CG Oncology appointed Isabel Kalofonos, a 20-plus-year biopharma commercial executive, as Chief Commercial Officer. She led launches at Crinetics (PALSONIFY), ImmunoGen (ELAHERE), and Takeda (TAKHZYRO), and will head commercial strategy ahead of a potential first launch of cretostimogene grenadenorepvec in bladder cancer.
Key figures
- Cretostimogene trial patients
- more than 400 patients with NMIBC
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.